Leighton
You are a broker, clearly more experienced than I in market dynamics. I have asked this question at least twice before and have never generated a response. Let me try again. Based on your experience as a broker, does it concern you at all that we have a company with a drug well into Phase III trials with allegedly promising efficacy against a terminal disease with no known cure or effective treatment that is selling for less than $3 on anemic daily volume?
We can all cite numerous examples of biotechs selling at reasonable valuations (not hype-driven ala Entremed) with much less apparent promise and broad applicability than Onconase at much earlier stages of FDA trials. IF, the Onconase trials are on track, don't you agree ACEL should be commanding a much higher multiple?
Leighton, you and rpg regularly accuse those of us who have grown impatient as being "naive, amateurish, greedy, uninformed" etc. I believe you do a disservice to some of my fellow "complainers", and even if I plead guilty to all the above (except greedy, I've only been in for 8+ years now)), I would ask you again for a factual response. Help me end my naivete'...as an "amateur" investor, should I be concerned that this company can still be bought for $2+ at this late date? Are you concerned??
Tom |
